Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abnormality in the P50 auditory-evoked potential gating is an endophenotype associated with schizophrenia.
|
12399955 |
2002 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Auditory P50 sensory gating deficits correlate with genetic risk for schizophrenia and constitute a plausible endophenotype for the disease.
|
20102668 |
2011 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The marker D15S1360 has been shown to be significantly linked with the phenotype of abnormal P50 suppression in schizophrenia families.
|
11803513 |
2001 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that P50 auditory evoked potentials can be recorded across multiple sites and reliably demonstrate a physiological abnormality in schizophrenia.
|
20382002 |
2010 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined the association of KMO polymorphisms with general neuropsychological performance and P50 gating in a sample of 150 schizophrenia and 95 healthy controls.
|
25464917 |
2014 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PERG results showed a significant increase of the P50 implicit time in schizophrenia patients compared with controls (t(55) = 2.1, p < .05, d = 0.55) and a significant increase of the N95 implicit time in schizophrenia patients compared with controls (t(55) = 4.2; p < .001, d = 0.66).
|
31353068 |
2019 |
Schizophrenia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Based on our data analysis, we suggest the activation of NF-kB as a possible pathway that links the deregulation of glutamate, calcium, apoptosis, and the activation of the immune system in schizophrenia patients.
|
31581776 |
2019 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diminished suppression of the P50 auditory evoked potential is a phenotype used in studies of genetic susceptibility in schizophrenia.
|
15625200 |
2005 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because P50 sensory gating deficit is a common neurophysiological dysfunction in patients with schizophrenia and schizophrenia spectrum disorders, it is conceivable to hypothesize that the human alpha7 neuronal nicotinic receptor subunit gene might be a susceptible gene for schizophrenia.
|
15531077 |
2004 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Deficits in gating of the P50 response have been shown to segregate with schizophrenia in this sample and may identify carriers of gene(s) predisposing for schizophrenia.
|
8094267 |
1993 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The P50 event-related potential sensory gating deficit, a failure to inhibit responses to repeated stimuli, is a leading endophenotype for schizophrenia (SZ).
|
20363872 |
2011 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As suggested by several studies, abnormal sensory gating measured by the P50 paradigm could be an endophenotype predisposing to schizophrenia.
|
14569275 |
2004 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CHRNA7 gene encoding the α7 nicotinic acetylcholine receptor (nAChR) has repeatedly been linked with schizophrenia and the P50 sensory gating deficit.
|
30974230 |
2019 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diminished gating of the P50 auditory evoked response to repeated stimuli is a psychophysiological feature of schizophrenia, that is also present in many relatives of patients.
|
1450287 |
1992 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adult-onset schizophrenia is generally associated with one parent who demonstrates abnormal P50 sensory gating and elevated anticipatory saccades and one parent who is normal on the physiologic measures (i.e., unilineal inheritance).
|
10206241 |
1999 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associated with alpha 7 nicotinic acetylcholine receptor (α7 nAChR) dysfunction and shown to be improved with nicotine and α7 nAChR agonists, SG has recently been shown to be improved in low P50 suppressing SCZ patients following acute CDP-choline treatment.
|
30920339 |
2019 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-five comparison and 42 schizophrenia subjects underwent P50 gating measurement and COMT genotyping.
|
17448448 |
2007 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
P50 amplitude may, therefore, be a sensitive marker of nicotinic dysfunction in individuals with familial risk for schizophrenia, which is mediated through mechanisms (e.g., α₄β₂ receptors) that are distinct from those (e.g., α₇ receptors) that mediate P50 gating.
|
22048129 |
2012 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the genetically HR group, abnormal P50 sensory gating was found only in offspring who met criteria for the schizophrenia prodrome.
|
15038993 |
2004 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated two neurophysiological endophenotypes of schizophrenia - P50 sensory gating and mismatch negativity in 22q11.2DS subject and evaluated their association with catechol O-methyltransferase (COMT) and proline dehydrogenase (PRODH) genetic variants.
|
23910792 |
2013 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A deficit in the inhibition of the P50 evoked response to repeated auditory stimuli has been characterized as a neurobiological deficit in schizophrenia.
|
10813805 |
2000 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The P50 deficit is inherited in schizophrenia pedigrees, but it is not sufficient for disease development and thus represents a predisposition factor.
|
8873294 |
1996 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A deficit in sensory gating measured by the suppression of P50 auditory event-related potential (ERP) has been implicated in the biological bases of schizophrenia and some other psychiatric disorders and proposed as a candidate endophenotype for genetic studies.
|
17014995 |
2007 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gating of the theta-alpha-frequency oscillatory signal in the paired-click paradigm is more strongly associated with schizophrenia and has significantly higher heritability compared with the traditional P50 gating.
|
18762587 |
2008 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Following reports of SG improvements in low P50 suppressing SCZ patients and healthy participants with the α7 agonist, CDP-choline, this pilot study examined the combined modulatory effect of CDP-choline (500 mg) and galantamine (16 mg), a nAChR positive allosteric modulator and acetylcholinesterase inhibitor, on SG to speech stimuli in twenty-four SCZ patients in a randomized, double-blind and placebo-controlled design.
|
30790597 |
2019 |